Tracks tumor DNA in blood to see if lung cancer treatment works
Checks blood tumor DNA changes to see if kinase inhibitors work in lung cancer.
Plain-language title generated from the registry record
Registry title: Analysis of Circulating Tumor DNA Dynamics to Predict and Monitor Response to TKI in Patients With Advanced NSCLC.
Key facts
- Where
- Ho Chi Minh City, VietnamSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT06167460, who can take part
Where in Vietnam
- Medical Genetics InstituteHo Chi Minh City, VietnamTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Gene Solutions
- Trial code
- NCT06167460
- Record updated
- 16 July 2025
- Original description
This is an observational study, aiming to investigate whether the ctDNA dynamics analyzed by the K-TrackTM assay could predict early response to Tyrosine kinase inhibitors (TKIs) in patients with advanced non-small cell lung cancer (NSCLC).Read full original descriptionShow less
Analysis of Circulating Tumor DNA Dynamics to Predict and Monitor Response to Tyrosine Kinase Inhibitors in Patients With Advanced Non-small Cell Lung Cancer
This is an observational study, aiming to investigate whether the ctDNA dynamics analyzed by the K-TrackTM assay could predict early response to Tyrosine kinase inhibitors (TKIs) in patients with advanced non-small cell lung cancer (NSCLC).
1. Determine relationship between ctDNA dynamics and clinical response to TKI,
* No response/progressive disease = ctDNA levels increase from baseline * Partial response/stable disease = ctDNA levels decrease from baseline * Complete response = ctDNA clearance. 2. Compare and combine ctDNA dynamics and RECIST1.1 to predict clinical response. 3. Determine relationship between ctDNA dynamics and progression free survival, overall survival.
Inclusion: Patients are diagnosed with advanced non-small cell lung cancer and indicated for TKI (first or second line). TKI combined with chemotherapy is allowed; FFPE/FNA sample is available; Compliant with treatment protocol; Patients consented to participate in the study.
Exclusion: Patients already started chemotherapy before enrollment; Medical or psychiatric conditions or occupational responsibilities that may preclude compliance with the protocol; Patients already started TKI before enrollment; Patients did not agree to participate in the studies.